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Effects of TMK-688, a potent 5-lipoxygenase inhibitor, 
on dual-phase asthmatic response in conscious guinea 
pigs sensitized with ovalbumin
Yuji Tohda, Masato Muraki, Hirokazu Kubo and Shigenori Nakajima 
Fourth Department of Internal Medicine, Kinki University School of Medicine, Osaka, Japan
ABSTRACT 
We evaluated the anti-asthmatic effects and 
mechanism of action of TMK-688, a potent 5-
lipoxygenase inhibitor, on the dual-phase asthmatic 
response and on airway inflammation in conscious 
guinea pigs sensitized with ovalbumin (OA). TMK-688 
inhibited both the immediate and the late asthmatic 
response (LAR) after administration of a single oral 
dose of 3.2 or 10mg/kg 2h before OA challenge. 
Pretreatment with TMK-688 also inhibited airway 
hyperresponsiveness to acetylcholine. The increase in 
eosinophils in bronchoalveolar lavage fluid and the 
production of reactive oxygen, an index of cell 
activation during LAR, was also suppressed by TMK-
688. These findings suggest the following inhibitory 
mechanism of LAR by TMK-688: (i) a reduction of
eosinophil accumulation in airways; (ii) the inhibition 
of the immediate asthmatic response; (iii) the inhibition 
of airway hyperresponsiveness; and (iv) the sup-
pression of the generation of reactive oxygen from 
bronchoalveolar lavage cells. 
Key words: airway hyperreactivity, bronchoalveolar 
lavage cell, dual-phase asthmatic response model, 
guinea pigs, late asthmatic response, reactive oxygen, 
TMK-688.
INTRODUCTION 
TMK-688 was developed as a potent 5-lipoxygenase 
inhibitor with histamine antagonism.1 When administered
orally, TMK-688 reduces leukotrienes B4 and C4 in both 
nasal-lavage fluids and in the lungs of allergen-
challenged guinea pigs.2 TMK-688 also shows anti-
anaphylactic activity on the passive cutaneous 
anaphylaxis (PCA) test in the rat and on the Forssman and 
Arthus reactions in the guinea pig.3 
 TMK-688 was developed as an anti-allergy agent. At 
an oral dose of 20mg/day TMK-688 has been shown, in 
clinical trials in Japan, to be safe and effective in adults 
with bronchial asthma.
 
In the present study we examined the effects of TMK-
688 on the dual-phase asthmatic response, including the 
immediate (IAR) and late asthmatic response (LAR), cell 
accumulation in bronchoalveolar lavage (BAL) fluid in 
ovalbumin (OA)-sensitized guinea pigs and non-specific 
airway hyperresponsiveness after acetylcholine (ACh) 
challenge in guinea pigs.
METHODS 
Animals and preparation of the dual-phase 
asthmatic model 
Male Hartley guinea pigs weighing 250-300g were 
purchased from Japan SLC (Shizuoka, Japan) and were 
used to prepare the dual-phase asthmatic model with 
Tohda's method.4 Guinea pigs were housed in a humidity 
and temperature-controlled room (12h:12h light: dark 
cycle) with free access to food and water.
 Andersson's methods was modified as follows. Guinea 
pigs received intraperitoneal injections of 30mg/kg 
cyclophosphamide (Shionogi Pharmaceutical Co. Ltd, 
Osaka, Japan). Two days later, 1mg/0.5mL OA (grade 
V; Sigma Chemical Co., St Louis, MO, USA) containing 
100mg aluminum hydroxide as an adjuvant (Wako Pure 
Chemical Industries, Osaka, Japan) was injected
intraperitoneally. Three weeks later, 10μg/0.5mL OA
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containing 100mg aluminum hydroxide was injected 
intraperitoneally for sensitization. Airway responsiveness 
after OA challenge was measured 3 weeks later.
Administration of compound 
TMK-688 was dissolved in Tween 80 (NIKKOL TO-10 M; 
Nippon Chemical, Tokyo, Japan) and was raised to a 
sufficient volume with double-distilled water. The final 
concentration of Tween 80 was 5%. Then, 3.2 or 10 
mg/kg TMK-688 was administered orally with a probe 
(Magen sonde; Natsume Seisakusyo Co. Ltd, Tokyo, 
Japan) to guinea pigs 2 h before OA or ACh challenge. 
Control guinea pigs received 4mL/kg of the appropriate 
vehicle.
Measurement of specific airway resistance 
Specific airway resistance was measured with Pennoch's 
methodb as follows. The guinea pig was placed inside a 
two-chambered body plethysmograph (PYLUN/2P: 
Chamber Model-P; Buxco Electronics Inc., Sharon, CT, 
USA). Box pressure was measured with a pressure 
transducer (DP-45; Buxco). Specific airway resistance 
(SAR; cmH2O/s) was calculated from the box flow signal 
with a non-invasive respiratory analyzer (PUMR+SAR; 
Buxco) .
 After baseline measurement of SAR, guinea pigs were 
challenged for 1min with OA aerosol (1mg OA/kg) 
administered with a nebulizer (DeVilbiss 646; Shizume 
Medical, Tokyo, Japan) directed into a face mask placed 
on the guinea pig. Specific airway resistance was 
measured at 1, 3 and 5min and every hour for 7h after 
challenge.
Airway hyperresponsiveness test with ACh 
challenge 
Airway hyperresponsiveness was measured with the same 
method used for SAR measurement. Saline or increasing 
concentrations of ACh (4.9, 9.8, 20, 39 and 78 p g/mL 
in saline) were aerosolized (8.2L/min) for 30s at 3 min 
intervals with a nebulizer. The airway hyperresponsiveness 
was measured before and after challenge (1, 3 and 5 
min and every hour for 7h after challenge). The airway 
hyperresponsiveness was calculated from the box flow 
signal as described by Pennoch.6
Measurement of cell content and cell 
con truction in BAL fluid after OA challenge 
Guinea pigs given vehicle or TMK-688 were divided into 
three groups, as described earlier, to determine the 
changes in cell content of BAL fluid before and 5 min and 
4h after OA challenge. Guinea pigs were anesthetized 
with 50mg/kg sodium pentobarbital, i. p. The trachea 
was cannulated with a probe at the caring. The lungs 
were lavaged four times with saline (5mL/kg) through the 
. Seventy to 80% of the lavage fluid was consistently 
recovered. An aliquot of the lavage fluid was centrifuged
(200g for 5min at 4℃) to pellet cells. The pellet was
resuspended in saline and the total number of cells was 
counted with a standard hemocytometer after staining 
with 0.2% trypan blue solution (Wako). The remainder of 
the lavage fluid was centrifuged at 200g for 5min for the 
differential cell counts. The pellet was stained with May-
Gruenwald Giemsa (Wako) and each cell was counted.
Measurement of reactive oxygen generation 
from BAL cells 
Cell preparation 
Bronchoalveolar lavage cells were obtained from OA-
sensitized guinea pigs with the method described earlier 
and w re resuspended with Hank's balanced salt solution 
(HBSS; Whittaker Bioproducts, Walkersville, MD, USA) at
1×106cells/mL.
Sample preparation 
Control solution Dimethylsulfoxide (Merck, Darmstadt, 
Germany) was diluted with HBSS to a concentration of 
0.5%. 
TMK-688 solution TMK-688 was dissolved in 
dimethylsulfoxide and was diluted with HBSS to 0.1, 0.5
and 1.0μg/mL.
Measurement of reactive oxygen generation from 
BAL cells
The cell suspension (80μL) was incubated with 20mL
TMK-688 solution or control solution for 10min at 37℃,
followed by the addition of 50μL luminol solution
(2×10-4mol/L; Futaba Medical, Tokyo, Japan). Luminol-
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dependent chem,iluminescence (LDCL) was measured 
with a lumiphotometer (TD-4000; Futaba Medical) after
stimulation with 50μL calcium ionophore A23187 (25
μg/mL; Sigma Chemical Co.). The integrated value for
600s at 37℃ was recorded.
Ethical standards 
All experiments were performed according to institutional 
guidelines for the care and use of laboratory animals.
Statistical analysis
Data are expressed as the mean±SEM and were
compared for statistically significant differences with the 
Student's t-test or Dunnett's statistics. Differences with a P 
value less than 0.05 were considered significant.
RESULTS 
Airway response after OA challenge in guinea 
pigs 
In each of the TMK-688-treated groups (3.2 or 10 
mg/kg) and in the untreated group, 10 guinea pigs were 
challenged with OA and changes in airway resistance 
were recorded. The IAR were observed 1-5min after 
challenge and LAR were observed 4-7h after challenge. 
In each animal, the difference in airway resistance before 
and after challenge was calculated to determine the 
increase in airway resistance. The mean integrated value
Table 1. Integrated value of change in specific airway 
resistance before and after challenge at the immediate and 
late asthmatic response in guinea pigs treated with TMK-688
  The occurrence of the immediate asthmatic response (IAR) and late 
asthmatic response (LAR) in ovalbumin-challenged guinea pigs. 
Guinea pigs were given either vehicle or TMK-688 orally 2h before 
challenge. Definitions of IAR and LAR are given in the Methods.
   Results are expressed as the mean±SEM. Differ nces between
guinea pigs not treated and treated with TMK-688 were assessed with
analysis of variance using Dunnett's statistics. *P<0.05 versus none.
1-5min after challenge (IAR) and that after 4-7h (LAR) 
are shown in Table 1. 
The increase in airway resistance with IAR was
26.03±0.81cmH2O/S in the untreated group. However,
the increase was slightly less in guinea pigs receiving 3.2
mg/kg TMK-688 (19.59±3.69) and was significantly
less in guinea pigs receiving 10mg/kg TMK-688 (10.87
±3.05).
  The increase in airway resistance with LAR was 6.85±
0.88 in the untreated group. However, the increases were
significantly less in groups treated with TMK-688 at both
3.2 and 10mg/kg (2.91±1.13 and 1.16±0.56,
respectively).
Airway hyperresponsiveness after ACh 
challenge in guinea pigs 
Figure 1 shows the effect of TMK-688 (3.2mg/kg) on 
SAR after ACh challenge. The SAR in unsensitized guinea 
pigs was not increased by challenge with ACh at doses up
to 78μg/mL. The increase in SAR was completely
blocked by TMK-688.
Fig. 1 Effect of TMK-688 on specific airway resistance (SAR) in 
guinea pigs challenged with acetylcholine (ACh). Guinea pigs 
were sensitized with ovalbumin before ACh challenge and 
received either vehicle or 3.2mg/kg TMK-688 2h before the 
first ACh challenge. Saline or increasing concentrations of ACh 
were nebulized for 30s at 3min intervals. Results are expressed
as the mean±SD. The significance of differences between the
two groups was assessed with Student's t-test. (*P<0.05;
**P<0
.01 vs unsensitized; ttP<0.01 vs control.) (▲),
unsensitized (n=3); (□), control (n=4); (◆), TMK-688 (n=3).
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Fig. 2 Cell content and construction in bronchoalveolar 
lavage fluid from guinea pigs given either vehicle or TMK-688 
(3.2 or 10mg/kg) orally 2h before ovalbumin (OA) challenge. 
Bronchoalveolar lavage was performed (a) before, (b) imme-
diately after or (c) 4h after OA challenae. Results are exaressed
as the mean±SD for at least five guinea pigs per group. The
significance of differences among groups was assessed with
analysis of variance using Dunnett's statistics (*P<0.05).
(□) sensitization+OA challenge; (図), sensitiization+TMK-688
(3.2mg/kg, p. o.) +OA challenge; (■), sensitizotion+TMK-
688 (10mg/kg, p. o.) +OA challenge.
Fig. 3 Effects of TMK-688 (図) on reactive oxygen generation
from bronchoalveolar lavage cells. Bronchoalveolar l vage
cells were incubated with TMK-688 (0.1, 0.5 and 1.0μg/mL)
for 10min at 37℃ followed by stimulation with calcium iono-
phore (A23187). As a positive control (□), bronchoalveolar
lovoge cells were incuba+ed without TMK-688. Figure 3
represents integrated values of luminol-dependent chemi-
luminescence. Results are expressed as the mean±SD. The
significance of differences among groups was assessed with
analysis of variance using Dunnett's statistics (*P<0.05).
Cell content in BAL fluid 
In BAL fluid obtained before OA challenge, the total 
numbers of cells and the numbers of cells of all types did 
not differ between the control group and the TMK-688-
treated groups (Fig. 2a).  
In BAL fluid obtained 5min after OA challenge (IAR) 
the numbers of cells of each type did not differ 
significantly between the three groups (Fig. 2b). In BAL 
fluid obtained 4h after OA challenge (LAR), the numbers 
of total cells, macrophages, and eosinophils in control
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animals were higher than before challenge or at 5min 
(Fig. 2c). 
 However, in animals that received TMK-688 2h before 
challenge, the increase in the numbers of total cells, 
macrophages and eosinophils were inhibited dose 
dependently by TMK-688. At a dose of 10mg/kg TMK-
688, the numbers of total cells and eosinophils were 
significantly lower.
Reactive oxygen-generating activity of BAL 
cells
TMK-688 at a dose of 1.0μg/mL significantly
suppressed the generation of reactive oxygen from BAL 
cells (Fig. 3).
DISCUSSION 
The LAR can occur after IAR in some asthmatic subjects 
challenged with an antigen7 and is suspected to be 
closely related to intractable asthma for several reasons. 
First, the airway during LAR is hyperresponsive to
stimulation.8,9 Second, conventional short-acting β2-
adrenoceptor agonists do not inhibit either LAR or the 
accompanying increase in non-specific airway 
responsiveness.10,11 Third, elevated levels of circulating 
blood eosinophils and bronchoalveolar eosinophilia are 
associated with LAR.12,13 Fourth, the tunica mucosa
tracheae is damaged in patients with LAR. Although IAR is 
thought to occur because of IgE-mediated events 
involving cell degranulation and mediator release, the 
mechanism governing LAR is still poorly understood. In 
sensitized subjects, LAR can be provoked with various 
allergens, including simple chemicals that are difficult to 
prove to be allergens, and is induced by exercise even in 
asthmatic patients.14 Although we cannot exclude the 
involvement of a non-immunologic mechanism in LAR, 
the association of airway inflammation with LAR is 
suspected.12
 Some investigators have reported that LAR is induced 
by inflammation after bacterial or viral challenge in 
animal models. Recently, inflammation due to allergy, 
especially that involving neutrophils, basophils, 
lymphocytes, monocytes and alveolar macrophages, is 
attracting attention. 
 Leukotriene is thought to play a major role as a 
chemical mediator in LAR. TMK-688 has been confirmed 
in vivo to inhibit leukotriene synthesis by inhibiting 5-
lipoxygenase.2 Because its profile suggests that it may be
effective as an anti-asthmatic, we have evaluated TMK-
688 in animals and in human subjects. In LAR in OA-
s nsitized guinea pigs, oral administration of 1-10 
mg/kg TMK-688 inhibits increases in leukotriene B4 and 
C4 in lung tissue.2 In asthmatic patients, oral 
administration of 20mg/day TMK-688 was useful (T 
Miyamoto et al., unpubl. obs.,1991). The doses used in 
these human and animal studies were consistent with an 
in vivo blood concentration sufficient to inhibit 5-
lipoxygenase activity.1 These findings suggest that 
inhibition of leukotriene synthesis is involved in the anti-
asthmatic action of TMK-688.
 
In the present study we counted the numbers of cells of 
different types in BAL fluid to investigate the mechanism 
of action of TMK-688 on LAR. At an oral dose of 3.2 
mg/kg, TMK-688 inhibited LAR and modulated the 
recruitment of eosinophils and neutrophils in BAL fluid. A 
close relationship between LAR and the influx of 
inflammatory cells into the bronchial lumen has been 
shown in some animal models.16-27 Therefore, TMK-688 
may prevent LAR by inhibiting the recruitment of 
inflammatory cells.
 We found that TMK-688 both inhibited the increase in 
SAR during IAR and inhibited the [AR. Robertson et al.28 
attribute the LAR of the dual-phase asthmatic response to 
a series of IgE-mediated events. The effects of TMK-688 
on SAR may result from the prevention of IAR, which may 
then inhibit the LAR. The effect of TMK-688 on [AR may 
result from the inhibition of immunologic mediators 
because TMK-688 is long-lasting and inhibits both the 
generation of leukotrienes in vivo and airway contraction 
induced by histamine challenge. In some histologic 
studies, airway inflammation was increased even in
patients with mild asthma.29,30 Ozone inhalation or viral 
inf ctio  cause inflammation and hyperreactivity in the 
airway.31-35 Airway inflammation is thought to play an 
important role in the development of bronchial asthma 
and in the increase in airway hyperresponsiveness. 
Reactive oxygen is thought to play an important role in 
airway inflammation. By generating reactive oxygen in 
response to various stimulants, such as leukotriene B436 
and platelet-aggregating factor,37 eosinophils induce
airway damage.38 Uenishi39 reported that the LDCL of 
BAL cells is increased in OA-challenged guinea pigs, that 
the peak value of LDCL correlates with the amount of 
antigen, that BAL cells are activated by OA-challenge 
and that they participate in the development of airway 
inflammation through the activation of eosinophils. He 
also reported that these factors were the cause of LAR.39
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In the present study TMK-688 inhibited the LDCL of
BAL cells at a final concentration of 1.0μg/mL. This
finding suggests that TMK-688 is related to the inhibition 
of LAR through the inhibition of inflammatory cell 
activation. 
 Asthmatic patients are hyperresponsive to broncho-
constrictors, such as histamine, methacholine and ACh. 
We investigated the effect of TMK-688 on airway 
hyperresponsiveness in ACh-challenged guinea pigs. 
TMK-688 inhibited airway hyperresponsiveness at an oral 
dose of 3.2mg/kg. Airway inflammation plays an
important role in increasing airway hyperresponsiveness. 
Histologic studies have revealed the presence of airway 
inflammation even in patients with mild asthma.40,41 
Activated inflammatory cells generate reactive oxygen 
species, such as superoxide42 and hydroperoxide,42 which 
are important in the inflammatory process. As BAL 
macrophages of asthmatic subjects generate more 
reactive oxygen than do those of normal subjects,43,44 
reactive oxygen may play a critical role in airway 
hyperresponsiveness. In the present study, TMK-688
inhibited reactive oxygen generation and airway inflam-
mation and then inhibited airway hyperresponsiveness to 
ACh. The ineffectiveness of TMK-688 against baseline 
lung resistance suggests that the inhibition of airway 
hyperresponsiveness was not due to bronchodilation. 
 The LAR in this model accurately reflects the pathology 
of intractable asthma. TMK-688 inhibits the increase of 
airway hyperresponsiveness and prevents the LAR. These 
findings suggest the usefulness of TMK-688 as an anti-
asthmatic drug.
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